Stoke Therapeutics, Inc. (STOK)

59.73 -5.47 (-8.39%) At close: 4:00PM EST

Stoke Therapeutics, Inc.

45 Wiggins Avenue
Bedford, MA 01730
United States
781 430 8200
http://www.stoketherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 56

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Edward M. Kaye	CEO & Director	668.37k	N/A	1949
Dr. Adrian R. Krainer Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	119.5k	N/A	1959
Mr. Stephen J. Tulipano CPA, CPA, MBA	Chief Financial Officer	514.47k	N/A	1959
Ms. Isabel Aznarez Ph.D.	Co-Founder, VP & Head of Biology	N/A	N/A	1972
Dr. Huw M. Nash Ph.D.	COO & Chief Bus. Officer	N/A	N/A	1967
Ms. Joan Wood	Head of HR	N/A	N/A	N/A
Dr. Gene Liau	Exec. VP, Head of Research & Preclinical Devel.	N/A	N/A	1955
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1960
Ms. Shamim Ruff	Sr. VP of Regulatory Affairs & Quality	N/A	N/A	1960
Ms. Nancy M. Wyant	VP & Head of Clinical Operations	N/A	N/A	1972

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Corporate Governance

Stoke Therapeutics, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.